Genomic impact of transient low-dose decitabine treatment on primary AML cells

Acute myeloid leukemia (AML) is characterized by dysregulated gene expression and abnormal patterns of DNA methylation; the relationship between these events is unclear. Many AML patients are now being treated with hypomethylating agents, such as decitabine (DAC), although the mechanisms by which it...

Full description

Saved in:

Bibliographic Details
Published in:	Blood Vol. 121; no. 9; p. 1633
Main Authors:	Klco, Jeffery M, Spencer, David H, Lamprecht, Tamara L, Sarkaria, Shawn M, Wylie, Todd, Magrini, Vincent, Hundal, Jasreet, Walker, Jason, Varghese, Nobish, Erdmann-Gilmore, Petra, Lichti, Cheryl F, Meyer, Matthew R, Townsend, R Reid, Wilson, Richard K, Mardis, Elaine R, Ley, Timothy J
Format:	Journal Article
Language:	English
Published:	United States 28.02.2013
Subjects:	Animals Antimetabolites, Antineoplastic - administration & dosage Antimetabolites, Antineoplastic - pharmacology Azacitidine - administration & dosage Azacitidine - analogs & derivatives Azacitidine - pharmacology Cells, Cultured CpG Islands - drug effects CpG Islands - genetics Decitabine DNA Methylation - drug effects DNA Methylation - genetics Dose-Response Relationship, Drug Gene Expression Profiling Gene Expression Regulation, Leukemic - drug effects Genome, Human - drug effects Humans Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - pathology Mice Microarray Analysis Primary Cell Culture Time Factors
ISSN:	1528-0020, 1528-0020
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!